Cargando…

The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy

PURPOSE: The purpose of this study is to investigate the role of fibroblast growth factor receptor 4 (FGFR4) polymorphism in esophageal cancer after chemoradiotherapy (CRT). MATERIALS AND METHODS: Peripheral blood samples from 244 patients treated with CRT for esophageal squamous cell carcinoma were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shim, Hyun-Jeong, Shin, Min-Ho, Kim, Hee-Nam, Kim, Jo-Heon, Hwang, Jun-Eul, Bae, Woo-Kyun, Chung, Ik-Joo, Cho, Sang-Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720088/ https://www.ncbi.nlm.nih.gov/pubmed/25989802 http://dx.doi.org/10.4143/crt.2015.018

Ejemplares similares

FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition
por: Cho, Sang Hee, et al.
Publicado: (2017)

Clinical Prognostic Factors for Locally Advanced Esophageal Squamous Carcinoma Treated after Definitive Chemoradiotherapy
por: Kim, Dae-Eun, et al.
Publicado: (2013)

Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility
por: Chou, Chia-Hsuan, et al.
Publicado: (2017)

FGFR4 GLY388ARG polymorphism modulates cancer patients' survival in pooled analysis
por: Frullanti, Elisa, et al.
Publicado: (2010)

FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis
por: Kim, Jung Han, et al.
Publicado: (2021)

Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis
por: Matakidou, A, et al.
Publicado: (2007)

Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis
por: Xiong, Si-Wei, et al.
Publicado: (2017)

The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer
por: Kim, Ka-Rham, et al.
Publicado: (2017)

FGFR4 c.1162G > A (p.Gly388Arg) Polymorphism Analysis in Turkish Patients with Retinoblastoma
por: Akdeniz Odemis, Demet, et al.
Publicado: (2020)

Benefits of Adjuvant Chemotherapy for Clinical T3-4N0 Rectal Cancer After Preoperative Chemoradiotherapy
por: Bang, Hyun Jin, et al.
Publicado: (2023)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021)

Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy: A retrospective cohort study
por: Shim, Hyun Jeong, et al.
Publicado: (2020)

FGFR4 Gly(388)Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls
por: Xu, Bin, et al.
Publicado: (2011)

FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition
por: Ye, Yanwei, et al.
Publicado: (2020)

Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
por: Qiu, Xiangnan, et al.
Publicado: (2020)

A rare case of highly differentiated follicular carcinoma in ovary with FGFR4 Gly388Arg polymorphism: a case report and literature review
por: Bao, Yi-Ting, et al.
Publicado: (2022)

Endoscopic Submucosal Dissection Followed by Concurrent Chemoradiotherapy in Patients with Early Esophageal Cancer with a High Risk of Lymph Node Metastasis
por: Kim, Hee Kyung, et al.
Publicado: (2019)

Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer
por: Kim, Yong-Hyub, et al.
Publicado: (2015)

Cardiac Dose Predicts the Response to Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
por: Ho, Yu-Chieh, et al.
Publicado: (2023)

FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients
por: Streit, S, et al.
Publicado: (2006)

G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis
por: Jézéquel, P, et al.
Publicado: (2004)

The role of MMP-1 and FGFR4-R388 gene polymorphisms in pituitary adenoma
por: Zlatkutė, Eglė, et al.
Publicado: (2017)

Adrenal Corticomedullary Mixed Tumor Associated With the FGFR4-G388R Variant
por: Kanzawa, Maki, et al.
Publicado: (2020)

Clinical Factors to Predict the Response to Concurrent Chemoradiotherapy and Survival in Esophageal Cancer Patients
por: Nam, Su Youn, et al.
Publicado: (2020)

Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
por: Chen, Chih-Yi, et al.
Publicado: (2018)

A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
por: Zhao, Chuanhua, et al.
Publicado: (2016)

Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma
por: Shi, Zhenguo, et al.
Publicado: (2022)

VEGF as a Predictor for Response to Definitive Chemoradiotherapy and COX-2 as a Prognosticator for Survival in Esophageal Squamous Cell Carcinoma
por: Yoon, Mee Sun, et al.
Publicado: (2011)

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
por: Park, Sehhoon, et al.
Publicado: (2019)

The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2018)

Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer
por: Peng, Tao, et al.
Publicado: (2021)

Is There a Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?
por: Zhang, Peng, et al.
Publicado: (2014)

Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy
por: Zhou, Xi‐Lei, et al.
Publicado: (2019)

GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma
por: Tsou, Yung-Kuan, et al.
Publicado: (2017)

(18)F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy
por: Lee, Seokmo, et al.
Publicado: (2021)

A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer
por: Zhu, Li-Li, et al.
Publicado: (2015)

STAT3β Enhances Sensitivity to Concurrent Chemoradiotherapy by Inducing Cellular Necroptosis in Esophageal Squamous Cell Carcinoma
por: Zheng, Zhen-Yuan, et al.
Publicado: (2021)

Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma
por: Kwon, Dohee, et al.
Publicado: (2016)

Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas
por: Wimmer, Eva, et al.
Publicado: (2019)

Gastrointestinal Hemorrhage after Concurrent Chemoradiotherapy in Locally Advanced Pancreatic Cancer
por: Lee, Kyong Joo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5qgrtmnbqgg0rk87618ltpdhmk